$40,000.00 in Sales Expected for TG Therapeutics, Inc. (NASDAQ:TGTX) This Quarter
Wall Street analysts expect that TG Therapeutics, Inc. (NASDAQ:TGTX) will report sales of $40,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 in the same quarter last year. The company is expected to announce its next quarterly earnings report on Monday, August 14th.
On average, analysts expect that TG Therapeutics will report full year sales of $40,000.00 for the current fiscal year, with estimates ranging from $150,000.00 to $160,000.00. For the next year, analysts anticipate that the company will post sales of $3.87 million per share, with estimates ranging from $150,000.00 to $15.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. TG Therapeutics had a negative net margin of 60,613.16% and a negative return on equity of 135.31%. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million.
TGTX has been the topic of several research reports. BidaskClub cut shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. Zacks Investment Research upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Thursday, July 13th. Raymond James Financial, Inc. restated a “buy” rating on shares of TG Therapeutics in a research report on Friday, April 21st. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research report on Monday, May 1st. Finally, Jefferies Group LLC initiated coverage on shares of TG Therapeutics in a research report on Tuesday, April 25th. They issued a “buy” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $23.67.
In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction on Monday, June 19th. The shares were sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the transaction, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at $5,295,075.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 16.70% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc raised its position in TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 384 shares during the last quarter. Creative Planning raised its position in TG Therapeutics by 3.2% in the first quarter. Creative Planning now owns 32,001 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 1,000 shares during the last quarter. Bank of America Corp DE raised its position in TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,395 shares during the last quarter. American International Group Inc. raised its position in TG Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 22,681 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 1,500 shares during the last quarter. Finally, UBS Group AG raised its position in TG Therapeutics by 34.4% in the first quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 3,736 shares during the last quarter. 46.23% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/20/40000-00-in-sales-expected-for-tg-therapeutics-inc-nasdaqtgtx-this-quarter.html.
Shares of TG Therapeutics (TGTX) traded up 4.688% during midday trading on Thursday, hitting $11.725. 899,815 shares of the stock were exchanged. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.35. The firm has a 50-day moving average of $11.27 and a 200-day moving average of $9.33. The company’s market capitalization is $722.92 million.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.